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Treatment of fungal infections is difficult due to several reasons, such as side effects
of drugs, emergence of resistant strains, and limited number of molecular targets for
the drug compounds. In fungi, heat shock proteins (Hsps) have been implicated in
several processes with the conserved molecular chaperone Hsp90 emerging as a
potential target for antifungal therapy. It plays key cellular roles by eliciting molecular
response to environmental changes, morphogenesis, antifungal resistance, and fungal
pathogenicity. Here, we evaluated the transcription profiles of hsp genes of the most
prevalent dermatophyte Trichophyton rubrum in response to different environmental
challenges including nutrient availability, interaction with cells and molecules of the
host tissue, and drug exposure. The results suggest that each Hsp responds to a
specific stress condition and that the cohort of Hsps facilitates fungal survival under
various environmental challenges. Chemical inhibition of Hsp90 resulted in increased
susceptibility of the fungus to itraconazole and micafungin, and decreased its growth in
human nails in vitro. Moreover, some hsp and related genes were modulated by Hsp90
at the transcriptional level. We are suggesting a role of Hsp90 in the pathogenicity and
drug susceptibility of T. rubrum as well as the regulation of other Hsps. The synergism
observed between the inhibition of Hsp90 and the effect of itraconazole or micafungin in
reducing the fungal growth is of great interest as a novel and potential strategy to treat
dermatophytoses.
Keywords: Hsp, antifungal therapy, molecular target, drug synergism, itraconazole, micafungin, 17-AAG
INTRODUCTION
Dermatophytes are pathogenic fungi and primary causative agents of superﬁcial mycoses in
humans (Brown et al., 2012). These fungi are keratinolytic and infect keratinized structures such as
skin, nails, and hair in the host, giving rise to diseases (also known as dermatophytoses or tineas)
such as athlete’s foot, onychomycosis, ringworm, and jock itch. Among the species belonging to
this group of ﬁlamentous fungi, Trichophyton rubrum is the leading cause of human skin and
nail mycoses and has high prevalence worldwide (Havlickova et al., 2008; Seebacher et al., 2008;
Nenoﬀ et al., 2014). Although rare, disseminated or deep dermatophytoses have been reported
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in immunocompromised or immunosuppressed patients (Gong
et al., 2007; Marconi et al., 2010; Lanternier et al., 2013).
Depending on the amplitude and the site of infection,
dermatophytoses can be diﬃcult to cure and often relapse post-
treatment, even in immunocompetent individuals (Gupta and
Cooper, 2008; Ghannoum and Isham, 2014).
Although a reasonable number of antifungal drugs are
commercially available, majority of the clinical drugs act on the
ergosterol biosynthesis pathway, thus restricting the number of
cellular targets. Besides, resistance to commonly used antifungal
drugs has been reported in dermatophytes and other human
pathogens, rendering the choice of drug challenging and
exacerbating the prospect of successful treatment (Martinez-
Rossi et al., 2008; Pfaller, 2012). Therefore, novel antifungal
targets have become the prime focus of several researchers in
the ﬁeld of medical mycology. Drug combinations and synergism
have been proposed as therapeutically desirable approaches to
decrease the development of resistance (Kontoyiannis and Lewis,
2002).
Evaluation of the interconnection among drug resistance,
stress response, and the signaling pathways activated in these
processes has been revealing key elements or the core circuitry
as targets for antifungal therapy (Cowen and Steinbach, 2008;
Shapiro et al., 2011). One such promising cellular candidate is
the heat shock protein 90 (Hsp90) (Wirk, 2011), a molecular
chaperone belonging to the highly conserved family of heat
shock proteins (Hsps). These proteins rapidly accumulate in the
cytosol in response to heat and environmental challenges such
as antifungal drugs, oxidative stress, and heavy metal exposure
among others. The heat shock response (HSR) is considered a
rescue mechanism that enables the cells to cope under stressful
conditions and protects from severe damage. The primary role of
Hsps is to sense and assist proper protein folding and refolding,
and direct them for degradation in case of misfolding, thereby
assuring proteome integrity and homeostasis (Lindquist and
Craig, 1988). Hsps act as molecular chaperones or transcriptional
regulators in a myriad of physiological functions. These proteins
are classiﬁed into several families based on their function and
molecular weight, which ranges from 9 to 110 kDa. Hsps
are also found in all organisms (Lindquist and Craig, 1988;
De Maio et al., 2012), and are involved in the assembly of
protein complexes, transport and sorting of proteins into the
proper cellular compartments, cell-cycle control, and protein fate,
among other functions. In fungi, Hsps have been implicated
in several processes, including pathogenicity, phase transition
in dimorphic fungi, and antifungal drug resistance. Hsps are
synthesized as an adaptive response to stress that contributes to
the survival of pathogenic microorganisms in the host (Burnie
et al., 2006; Brown et al., 2010).
Heat shock protein 90 is highly abundant in cells even in non-
stressful state and increases further in response to diﬀerent forms
of stress. However, some eukaryotes present two hsp90 genes,
one inducible and the other constitutively expressed (Taipale
et al., 2010). Hsp90 can associate with several proteins involved
in signaling, metabolism, cell growth, transcription, protein
traﬃcking, chromatin remodeling, and stress response, among
others (Leach et al., 2012b). It is an ATP-dependent chaperone
and functions as a dimer. Each monomer presents an amino-
terminal domain (NTD) that binds ATP and hydrolyzes upon
association with the target proteins, a middle domain (MD)
crucial for the interaction with the target proteins, and a carboxyl-
terminal domain (CTD) responsible for dimerization. The energy
produced by the hydrolysis of ATP is used by Hsp90 to fold the
target proteins to their active conformations (Taipale et al., 2010).
By chaperoning the target proteins, Hsp90 can modulate several
downstream processes and regulatory cascades, thus controlling
the responses to dynamic environments (Shapiro et al., 2011;
Leach et al., 2012b).
Inhibitors of Hsp90 have been thoroughly searched for
and some natural compounds produced by microorganisms
have been isolated. These include geldanamycin, which is a
benzoquinone ansamycin derived from actinomycetes, and a
resorcyclic acid lactone called radicicol produced by certain
fungal species (Piper and Millson, 2012). Some Hsp90 inhibitors
are in clinical trial for cancer therapy and derivatives of natural
compounds have been synthesized to increase eﬃcacy and
decrease side eﬀects and toxicity (Gorska et al., 2012). In general,
these inhibitors act as ATP competitors and interfere with
the ATP-binding domain, which turns Hsp90 non-functional
and leads to the ubiquitination and proteasome degradation
of target proteins because of their aberrant conformation
(Wirk, 2011). Besides their therapeutic potential, geldanamycin
and its derivatives have been used to characterize the role
of Hsp90 in fungal adaptation to host environment and
antifungal resistance, as well as to understand their synergism
with other antifungal drugs. A promising and interesting
consequence of Hsp90 inhibition was that the emergence of
resistance to azoles and echinocandins were reduced in vitro in
human pathogens Candida albicans and Aspergillus fumigatus,
respectively, thus validating the eﬃciency of these antifungal
drugs in experimental infection models (Cowen, 2008; Cowen
et al., 2009). Compromising the Hsp90 function was also eﬀective
against C. albicans and A. fumigatus bioﬁlms, which are highly
drug-resistant recalcitrant structures and an important cause of
mortality. Targeting Hsp90 with chemical inhibitors increased
the susceptibility of C. albicans bioﬁlms to azoles in vitro and
in an animal infection model, and the eﬃcacy of azoles and
echinocandins against A. fumigatus bioﬁlms (Robbins et al.,
2011). In C. albicans, inhibition of Hsp90 also aﬀected cell wall
biogenesis by disrupting the signaling pathways involved in cell
wall remodeling (Leach et al., 2012a). Additionally, this also
impaired the Hsf1–Hsp90 auto-regulatory circuit in C. albicans.
The heat shock transcription factor Hsf1 governs the HSR and
is a target of Hsp90. Thus, Hsp90 inhibition aﬀected the Hsf1
regulon, consequently the regulation of HSPs and the resistance
to proteotoxic stress (Leach et al., 2012a).
In this work, we have chemically inhibited Hsp90 in the
dermatophyte T. rubrum and analyzed the eﬀects to assess
the roles played by this molecular chaperone in response to
antifungal drugs, fungal pathogenicity, and regulation of other
genes. To analyze drug susceptibility, three molecules with
diﬀerent modes of action were tested; itraconazole (ITRA),
5-Fluorocytosine (5-FC), and micafungin (MCFG) act on
ergosterol biosynthesis, nucleic acids, and glucan synthesis,
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respectively. The antifungal eﬀects of these drugs in synergy
with the Hsp90 inhibitor against the growth of T. rubrum were
evaluated. In order to analyze the role of Hsp90 in pathogenicity,
the ability of T. rubrum to colonize human skin and nail in
the presence of Hsp90 inhibitor was tested in an ex vivo model
of infection. The inﬂuence of Hsp90 in the regulation of hsp
genes and other related genes such as those encoding for the
heat shock factor Hsf1 and the pH responsive regulator PacC
was evaluated by transcription proﬁle analyses in response to
nutritional sources. Finally, in order to assess the adaptive
response to various stress conditions, the transcriptional proﬁle
of Hsps, including Hsp90, was evaluated after exposure of
T. rubrum to antifungal drugs and substrates present in the host.
MATERIALS AND METHODS
Trichophyton rubrum Strain
Trichophyton rubrum strain CBS118892 (CBS-KNAW Fungal
Biodiversity Centre) was cultivated inmalt extract agar (MEA: 2%
peptone, 2% glucose, 2% agar, pH 5.7) at 28◦C. To prepare the
conidia suspension, 15-day-old plates were ﬂooded with sterile
0.9% NaCl and the suspension ﬁltered through ﬁber glass to
remove mycelia debris. The conidia concentration in the ﬁltrate
was estimated using a Neubauer chamber, as previously described
(Persinoti et al., 2014).
Antifungal Drug Susceptibility Test
The synergistic eﬀect between chemical inhibition of Hsp90
and antifungal agents was tested by the following method:
T. rubrum conidia (1 × 106 per plate) were spread on the
surface of MEA containing 10, 100, and 300 μM of the
inhibitor 17-AAG (17-allylamino-17-demethoxygeldanamycin;
InvivoGen, San Diego, CA). E-test (AB Biodisk, Solna, Sweden)
gradient strips of ITRA, 5-Fluorocytosine (5-FC), or MCFG were
then placed on these plates. Gradient concentration of the tested
antifungal drugs ranged from 0.002 to 32 μg/mL and the results
were observed after incubation at 28◦C for 5 days. Plates without
antifungal agents were used to assess fungal development in
the presence of 17-AAG. Three independent experiments were
conducted.
Ex vivo Pathogenicity Test
The ex vivo nail and skin interaction assays were performed as
described here. Autoclaved small pieces of human nail obtained
from healthy donors were infected with 1 × 104 T. rubrum
conidia and incubated at 28◦C for 5 days, in the absence or
presence of 50, 100, or 200 μM of Hsp90 inhibitor 17-AAG.
After incubation, nail fragments were observed under a light
microscope to evaluate the hyphal development and fungal
morphology.
Small pieces of human skin were obtained from patients
who underwent abdominal surgery at the University Hospital
of Ribeirão Preto Medical School, University of São Paulo,
Brazil (HC-FMRP-USP). After removal of the adipose tissue,
the small pieces of human skin were infected with 1 × 104
T. rubrum conidia in the absence or presence of 200 μM 17-
AAG and incubated at 28◦C for 5 days. Infected skin fragments
were maintained in skin graft ﬂuid (SGF; Duek et al., 2004)
supplemented with or without 200 μM 17-AAG. Scanning
electron microscopy (SEM) was employed to visualize hyphal
development. For this purpose, the skin fragments were ﬁxed
with 3% glutaraldehyde in 0.1% phosphate buﬀer (pH 7.2) at 4◦C
for 2 h, rinsed with 0.1% phosphate buﬀer (pH 7.2), and post-
ﬁxed with 1% osmium tetroxide for 2 h. Samples were dehydrated
by a graded ethanol series and sputter-coated with gold to obtain
a layer of approximately 200 μm thickness. The samples were
viewed under a Jeol JSM -6610 LV scanning electron microscope
at an acceleration voltage of 25 kV.
Growth Conditions for Gene Expression
Assays
T. rubrum conidia (1 × 106) were inoculated in 100 mL of
malt extract (ME) medium (pH 5.0) or keratin medium (KM:
2.5 g/L keratin powder, MP Biomedicals, suspended in water,
pH 5.0). After shaking at 28◦C for 96 h, the resultant mycelia
were ﬁltered, frozen in liquid nitrogen, and stored at -80◦C
for expression studies. For the Hsp90 chemical inhibition assay,
fresh mycelia grown for 96 h at 28◦C in ME or KM were
incubated for 30 or 90 min at 28◦C with 100- or 300 μM
17-AAG. For antifungal drug response assays mycelia grown
in ME at 28◦C for 96 h were aseptically transferred to RPMI
1640 (Life Biotechnologies—buﬀered with 0.167M MOPS, pH
7.0) in the absence (control) and presence of sub-inhibitory
concentrations of acriﬂavine (ACR; 1.75 μg/mL) or terbinaﬁne
(TRB; 0.2 μg/mL), and incubated for 3 h at 28◦C.
For the interaction assays, the small pieces of human skin
were cleaned, infected with 1 × 104 T. rubrum conidia, and
incubated at 28◦C for 96 h. The fungus was then harvested and
used for total RNA extraction. For the nail interaction assay,
each human nail fragment was exposed to 1 × 104 T. rubrum
conidia and incubated at 28◦C for 96 h. The infected nail
fragments were vortexed to release fungal mycelia for total RNA
extraction and the nails discarded. The interaction assays were
approved by the local Ethics Committee (Protocol No. 046/2009).
Three independent experiments were conducted for each growth
condition and interaction assay.
Gene Expression Analysis
Total RNA was isolated from frozen mycelia using Illustra
RNAspin Mini RNA Isolation Kit (GE Healthcare). First-strand
cDNA was synthesized using the SuperScriptIII First-Strand
Synthesis Super Mix for qRT-PCR kit (Invitrogen). Both RNA
extraction and cDNA synthesis were performed according to
the manufacturer’s recommendations. An intron ﬂanking region
of the β-tubulin gene was used as positive control to verify
DNA contamination and proper cDNA synthesis, as previously
described (Jacob et al., 2012).
Speciﬁc primer pairs for each T. rubrum gene were designed
using the Primer Express v.3 software (Life Technologies) and are
listed in Table 1. qRT-PCR reactions were carried out in a ﬁnal
volume of 12.5 μL, containing 6.25 μL Power SYBRGreen PCR
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TABLE 1 | Primers used for qPCR assays.
Gene Accession numbera Primer sequences (5’– 3’) Amplicon length (bp) Efficiency(%)
hsp20 TERG_01659 F: GCCAAGGAGGAGTTGAATCCT
R: AGCCCTCTCCAATCTCGTCTT
57 95.29
hsp60 TERG_04141 F: AAGCGTCGTTGTCGGTAAGC
R: TGTCGAAGCCACGGTTAAAGT
62 92.6
hsp70 TERG_01883 F: CCGCCATGAACCCTGAGA
R: CGAATCGTCGTCCGATAAGAC
60 96.0
hsp70-like TERG_06505 F: CACGTACTCCTGCGTGGGTAT
R: TGCGGTTTCCCTGATCGT
71 96.0
hsp clpa TERG_07049 F: CCGGCAGTCTCCCAAGTCT
R: GTAGGCAGCAGCCATGACTTC
60 91.8
hsp88-like TERG_07658 F: AAGGGTGTCACCGCTGATG
R: TCAGTCTAGCCTTGAGCTTGCA
61 95.8
hsp90 TERG_06963 F: ACCGTGCTGCCCTTGCT
R: GTGATCTCGTCGCCAGACTTG
61 96.0
cdc37 TERG_06398 F: GAGATCGCAACTCTAGGGTACGA
R: GCCCGTCAATCCGTTTCA
64 93.5
hsp ssc1 TERG_03206 F: ACCGAGTCCGTCAAGAGCAT
R: TCGTCGGGATTAACGGACTT
59 96.1
hsp78 TERG_07949 F: CCGGTCTCAGCGGTGAAA
R: GGTGGGCCCAAGAAACATG
56 92.6
hsf1 TERG_04406 F: AGTGCTGGAGGCCGAGAAG
R: TCCCGACCCGAGAGCAA
60 97.4
pacC TERG_00838 F: TCCCAGCAGCCCCAAC
R: ATGTGGGAGGTGATGTGGT
63 98.3
aDermatophytes genome database accession number (http://www.broadinstitute.org/annotation/genome/dermatophytecomparative).
Master Mix (Life Technologies), 1.0 μL of each primer (hsp20,
250 nM; hsp60, 500 nM; hsp70, 450 nM; hsp70-like, 350 nM; hsp
clpa, 300 nM; hsp88-like, 350 nM; hsp90, 300 nM; cdc37, 400 nM;
hsp ssc1, 400 nM; hsp78, 350 nM; hsf1, 350 nM; pacC, 350 nM),
2.0-μL template cDNA (50 ng), and 3.25-μL ultra-pure water.
Thermal conditions for qRT-PCR were 95◦C for 10min, followed
by 40 cycles of 95◦C for 15 s and 60◦C for 1 min. All reactions
were performed in triplicate in 96-well reaction plates using
the StepOnePlus Real-Time PCR System (Life Technologies).
A melting curve for each gene was obtained and 2% agarose
gel electrophoresis was performed to conﬁrm the ampliﬁcation
of the unique product of expected size for each hsp gene. To
determine PCR eﬃciency, standard curves were generated using
cDNA sample at ﬁve-point, twofold dilutions and measured in
triplicates. The reference genes rpb2 and actin were used for
data normalization as previously described (Jacob et al., 2012).
Relative expression was calculated by the 2−CT method (Livak
and Schmittgen, 2001). Statistical signiﬁcance was evaluated by
one-way ANOVA followed by the Tukey’s ad hoc test, using the
GraphPad Prism v 5.1 Software.
RESULTS
Inhibition of Hsp90 by 17-AAG
In order to evaluate the synergism of Hsp90 with other antifungal
drugs, as well as its role in T. rubrum pathogenicity, 17-
AAG was used to chemically inhibit Hsp90 expression in
T. rubrum. Although inhibition of Hsp90 using 300 μM of
17-AAG had no eﬀect on T. rubrum growth in MEA, an
increase in fungal susceptibility to ITRA andMCFGwas observed
(Supplementary Figure S1). This was demonstrated by 10- and
fourfold decreases in minimal inhibitory concentration (MIC)
values, respectively. Moreover, there was no eﬀect when the
fungus was challenged with 5-FC (Table 2). The role of Hsp90
in T. rubrum pathogenicity was also analyzed using an ex vivo
nail interaction assay. Inhibition of Hsp90 decreased T. rubrum
growth on human nail in vitro. This decrease was dependent on
the concentration of 17-AAG used, and at 200 μM, T. rubrum
growth was almost entirely inhibited (Figure 1), indicating the
attenuation of fungal virulence. However, SEM of ex vivo human
skin inoculated with T. rubrum conidia showed no signiﬁcant
diﬀerence in fungal growth whenHsp90 was inhibited at the same
17-AAG concentration. (Supplementary Figure S2). This suggests
that other virulence factors or incomplete inhibition of Hsp90
activity might foster fungal growth in the ex vivo skin model.
TABLE 2 | Synergism of heat shock protein 90 (Hsp90) inhibition and
antifungal drugs.
17-AAG (µM) MIC (µg/mL)
5-Fluorocytosine
(5-FC)
Itraconazole
(ITRA)
Micafungin
(MCFG)
0 >32 0.125 0.008
10 >32 0.125 0.008
100 >32 0.125 0.004
300 >32 0.012 0.002
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FIGURE 1 | Effect of heat shock protein (Hsp90) inhibition on Trichophyton rubrum growth in human nail. Light microscopy was used to analyze hyphal
development in human nail fragments infected with T. rubrum conidia in the absence (positive control) or presence of the Hsp90 inhibitor 17-AAG (50, 100, or
200 μM) after 5 days at 28◦C. Negative control consists of uninoculated and untreated nails. Asterisks indicate nail fragments.
Expression Profile of hsps and Related
Genes
The expression of several hsps and related genes is modulated
during the growth of T. rubrum in KM and ME in the presence
of Hsp90 inhibitor 17-AAG. For some genes, this eﬀect is time-
and concentration-dependent (Figure 2). While the inhibition
of Hsp90 led to decreased accumulation of hsp70-like and hsf1
transcripts, regardless of the growth medium, the levels of
hsp60 and hsp88-like transcripts were decreased in response
to ME and KM, respectively. However, hsp70 and hsp clpa
genes were upregulated in the absence of Hsp90 activity, which
led to increased accumulation of hsp90 transcripts, perhaps in
an attempt to compensate for the chemical inhibition of the
protein. Interestingly, pacC was downregulated when Hsp90
was inhibited in the presence of keratin. Moreover, the gene
coding for the Hsp90 co-chaperone cdc37 was upregulated
in ME but not in KM, whereas hsp ssc1 was upregulated
only in KM (Figure 2) upon Hsp90 inhibition. These results
suggest a regulatory role for Hsp90 in the expression of pacC
and other hsp genes in T. rubrum, depending on the growth
medium.
Given the involvement of Hsps in the pathogenicity of several
fungal pathogens and in drug susceptibility, the expression proﬁle
of some of these hsp genes was evaluated in T. rubrum in
response to other antifungal drugs, such as TRB and ACR,
and during its growth on nail and skin fragments (Figure 3).
The analysis revealed diﬀerent expression proﬁles in response
to these environmental challenges. While hsp clpa gene was not
modulated in response to any stimuli analyzed (Figures 3A,B),
hsp90, hsp88-like, and hsp20 transcripts accumulated in response
to drug exposure (Figure 3B). However, hsp60 and hsp78
presented a slightly broad range of modulation with transcripts
accumulating during growth on nails and in response to one or
both drugs (Figures 3A,B).
DISCUSSION
Dermatophytes aﬀect millions of individuals annually and have
become an important public health concern because of their
refractivity to therapy, which prolongs the duration of treatment
especially in aging populations (Coelho et al., 2008; Martinez
et al., 2012). Because both the host and the pathogen are
eukaryotic organisms, treatment of fungal infections is diﬃcult
due to the limited number of antifungal targets available
(Martinez-Rossi et al., 2008). Another concern is the emergence
of resistance to antifungal drugs currently in clinical use.
Thus, it is necessary to identify new strategies for therapy
against fungal infections. In this study, we observed that it is
possible to increase the eﬃcacy of antifungal drugs, ITRA and
MCFG, by targeting the molecular chaperone Hsp90 with 17-
AAG, an inhibitor of the Hsp90 ATPase activity. Interestingly,
these antifungal agents have diﬀerent mechanisms of action.
While ITRA inhibits the enzyme lanosterol 14α-demethylase,
thus preventing the biosynthesis of ergosterol, a key sterol
in the fungal membrane (Lupetti et al., 2002; Odds et al.,
2003), MCFG inhibits the enzyme 1, 3-β-D-glucan synthase,
thereby blocking the biosynthesis of a key linker molecule in
the fungal cell wall (Onishi et al., 2000). When challenged
with antifungal drugs, several dermatophytes generally react
by activating stress responses (Paião et al., 2007; Yu et al.,
2007; Zhang et al., 2009; Peres et al., 2010), which often
depends on the Hsp90 chaperone. Hsp90 can associate itself
with a myriad of target proteins such as its co-chaperones and
functional regulators, and modulate the activation and stability
of the complex. Thus, functional inhibitors of the Hsp90 that
act on its ATPase-coupled conformation (Siligardi et al., 2002;
Lotz et al., 2003) disassemble the molecular complex of Hsp90
with co-chaperones and target proteins, thereby abrogating
drug resistance and increasing the eﬃcacy of traditional
antifungal drugs (Veri and Cowen, 2014). Although Hsp90 is
conserved among eukaryotes, it presents some conformational
diﬀerences in fungi, especially in regions such as the ATP
binding and the MDs that could be selectively targeted by
the chemical inhibitors (Wider et al., 2009; Shahinas et al.,
2015). Alternatively, it is possible to interfere with the Hsp90
targets or functional regulators, thus expanding the possibility
to ﬁnd clearer discrepancies between the pathogen and the
host (Veri and Cowen, 2014). Therefore, targeting Hsp90 or
other related proteins may be a viable alternative to treat
fungal infections caused by T. rubrum and probably by other
dermatophytes as well. We have also shown that the Hsp90
chaperone has a role in conferring the fungus with the ability
to colonize human nails in vitro. The involvement of this
chaperone in the pathogenicity of other pathogens such as
C. albicans and C. glabrata has been demonstrated (Noble
et al., 2010; Leach et al., 2012b; Singh-Babak et al., 2012).
Thus, blocking the action of Hsp90 in dermatophytes becomes
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FIGURE 2 | Effect of Hsp90 on the expression of hsp and related genes in T. rubrum. qRT-PCR analyses of the hsp and related genes of T. rubrum grown in
malt extract (ME) or keratin medium (KM) in the absence or presence of Hsp90 inhibitor. Gene expression levels are represented by the quantities of mRNA in each
condition relative to the control (ME). Data are represented as mean ± SD from three independent experiments with reactions performed in triplicate. Tukey’s ad hoc
test was used for statistical analysis ; ∗P < 0.05.
a potential strategy that combines this therapy with conventional
antifungal drugs, which would enhance the overall outcome of
the treatment.
The broad spectrum of Hsp90 functions were conﬁrmed by
changes in the expression proﬁle of various hsp and related
genes upon chemical inhibition of this chaperone in T. rubrum.
Moreover, these changes in gene expression in the fungus were
nutrient-dependent (ME and KM medium). The heat shock
transcription factor Hsf1 positively regulates the transcription
of the hsp90 gene in C. albicans and Saccharomyces cerevisiae;
both pharmacological inhibition and genetic depletion of Hsp90
correlate with Hsf1 activation in response to thermal stress
(Wu, 1995; Leach et al., 2012b). However, hsf1 transcript levels
decreased when T. rubrum was challenged with the Hsp90
inhibitor in MEA or KM, under non-stressful temperature
conditions (Figure 2). Additionally, there was an evident increase
in hsp90 transcripts in T. rubrum treated with the Hsp90
inhibitor, which was likely to compensate for the absence
of Hsp90 function (Figure 2). This suggests a regulatory
role for Hsp90 over hsf1 transcript levels or a compensatory
mechanism upon Hsp90 inhibition, in which most of the
hsf1 transcripts in the cell are eﬃciently transduced into
protein, in turn aiding hsp90 transcription. In T. rubrum,
putative DNA-binding sites for Hsf1 in the hsp90 promoter
region enable direct regulation. Another interesting observation
from this study is the decreased amount of the pacC
transcripts during growth in keratin cultures containing 17-
AAG (Figure 2). The transcription factor PacC mediates diverse
metabolic events, including virulence and keratinolytic activity,
in T. rubrum (Ferreira-Nozawa et al., 2006; Silveira et al.,
2010; Martinez-Rossi et al., 2012), suggesting a correlation
between the pacC and hsp90 genes and fungal virulence.
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FIGURE 3 | Transcript levels of T. rubrum hsp genes in response to environmental challenges. (A) qRT-PCR analyses of the transcript levels of hsp genes
of T. rubrum grown in malt extract (control), human nail, or human skin fragments for 96 h. (B) Mycelia were transferred to RPMI medium in the absence (control) or
presence of sub-inhibitory doses of terbinafine (TRB) or acriflavine (ACR) for 3 h for assessment of drug response. mRNA quantity in each condition relative to the
control are represented as mean ± SD from three independent experiments with reactions performed in triplicate. Tukey’s ad hoc test was used for statistical
analysis, ∗P < 0.05.
Additionally, we observed an increased accumulation of
some hsp transcripts on Hsp90 inhibition, while others,
including those belonging to the same family, suﬀered drastic
decline. For example, regardless of the culture condition,
transcription of the hsp70-like gene showed a signiﬁcant
reduction, whereas hsp70 transcripts increased signiﬁcantly and
hssc1 (Hsp70 family protein) transcripts practically accumulated
to the same amount, suggesting diﬀerent roles for each Hsp
(Figure 2).
In order to evaluate the expression proﬁles of some hsp genes
in ex vivo models, as well as during treatment with antifungal
drugs, T. rubrum was cultured in MEA or in nail or skin
fragments (Figure 3A) and in RPMI medium containing sub-
inhibitory concentrations of TRB or ACR (Figure 3B). hsp90
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gene expression increased only in response to TRB, an antifungal
used to treat dermatophytosis. Unexpectedly, hsp90 transcript
levels were similar to those observed in other experimental
conditions tested, including the human nail, in which the fungus
was dependent on Hsp90 function when this substrate was its
sole nutrient source. It is possible that the fungus depends on
similar amounts of the Hsp90 protein to cope with varying
culture conditions. The transcription proﬁle of the hsp clpA
gene was unchanged in the analyzed conditions, demonstrating
constitutive expression in response to various antifungal drugs
and growth conditions. However, there was an increase in
hsp20, hsp60, hsp78, and hsp88-like gene transcript levels when
T. rubrumwas challenged with ACR and/or TRB, suggesting their
involvement in cellular stress responses. An increase in hsp60 and
hsp78 transcripts was also observed when the fungus was grown
in nail fragments, suggesting that Hsp60 and Hsp78 proteins act
as Hsp90 co-chaperones in nail infections.
CONCLUSION
Complex formation of Hsp90 and its chaperones depends on
an ATPase-coupled conformational cycle, which links ATP
binding and hydrolysis. This is a highly conserved mechanism
in eukaryotic organisms, including C. albicans and other human
pathogenic fungi, since ATP binding and hydrolysis are essential
for Hsp90 function. Functional inhibition of ATP binding to
Hsp90 disassembles the molecular complex between Hsp90 with
target proteins and co-chaperones, consequently abrogating drug
resistance and increasing the eﬃcacy of traditional antifungal
drugs such as ITRA and MCFG. Blocking the Hsp90 activity
drastically decreased the ability of T. rubrum to grow on human
nail fragments and interfered with the modulation of some hsp
genes and the pacC gene, a regulator involved in T. rubrum
virulence. Thus, blocking Hsp90 function in dermatophytes is
suggested as a potential strategy for combination of this therapy
with traditional antifungal drugs, which would enhance the
antifungal eﬃcacy. This is an attractive hypothesis to be explored
further probably using in vitro and/or ex vivomodels of infection
as well as new inhibitors for Hsp90 and other co-chaperones.
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